ConductScience.org, home
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
API referenceFor AI assistants

Trial · NCT07908381

Registered outcomes20

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 20

Download this page as JSON
ListOutcomeTime frameDescription
PrimaryTime to complete resolution of all 13 RSV symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) symptom scaleDay 1 through Day 21
SecondaryNumber of participants with hospitalization due to RSVDay 1 through Day 35
SecondaryNumber of participants with hospitalization or death due to any causeDay 1 through Day 35
SecondaryNumber of participants who diedDay 1 through Day 35
SecondaryNumber of participants with non-protocol defined medical visits for any causeDay 1 through Day 35
SecondaryTime to complete resolution of RSV LRTD symptoms by RiiQDay 1 through Day 21
SecondaryTime to complete resolution of all 29 RSV parameters as assessed by RiiQ symptom scale scoreDay 1 through Day 21
SecondaryTime to alleviation of LRTD symptoms by RiiQDay 1 through Day 21
SecondaryTime to alleviation of all 13 RSV symptoms as assessed by RiiQDay 1 through day 21
SecondaryTime to alleviation of all 29 RSV parameters as assessed by RiiQDay 1 through Day 21
SecondaryTime to complete resolution of RSV infection symptoms as assessed by PGI-S scaleDay 1 through Day 35
SecondaryTime to resolution to pre-existing symptomsDay 1 through Day 21
SecondaryNumber of participants requiring mechanical ventilationDay 1 through Day 35
SecondaryNumber of participants requiring supplemental oxygen in hospitalDay 1 through Day 35
SecondaryNumber of participants requiring ICU admissionDay 1 through Day 35
SecondaryChange from baseline in RSV viral loadUp to Day 35
SecondaryPercentage of participants with RSV RNA viral load TNDUp to Day 35
SecondaryTime to RSV RNA viral load TNDUp to Day 35
SecondarySafety as measured by frequency of adverse events (AEs)Day 1 through Day 35
SecondaryPlasma Concentrations of zelicapavirAt Day 7

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07908381/registered

API referenceFor AI assistants